The Canadian MPS Society met directly with Takeda Pharmaceuticals on May 11th, when Takeda shared with us that they will discontinue development of TAK-609, investigational intrathecal enzyme replacement therapy for MPS II, Hunter syndrome.
Patients with MPS II currently on this treatment will continue to receive TAK-609. This is disappointing news to the MPS community however, we are very pleased to announce that team at Takeda is committed to making TAK-609 available to all those currently receiving this therapy until some other CNS-targeting therapy is approved by regulators in a patient’s relevant jurisdiction. MPS II individuals affected directly by this news will continue to be treated.
The letter to the Society with additional details provided from Takeda can be found in full here. Please don’t hesitate to contact us if you have any questions or concerns, or you may reach out to the Takeda team via the email addresses in the attached letter.